← Immuneering Corp (IMRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Immuneering Corp (IMRX)
Pharmaceutical Preparations · market cap $290M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Immuneering Corp (IMRX) is a clinical-stage pharma with a $133M market cap and ~$47M cash (roughly 7.7 months of runway). Its lead asset, atebimetinib, is in Phase 3 for pancreatic cancer, while two additional assets — IMM-1-104 and IMM-6-415 — are in early Phase 2 for advanced solid tumors. The company has generated no meaningful revenue and carries an elevated short interest of ~58% of float.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Atebimetinib | Phase 3 | Pancreatic Cancer |
| IMM-1-104 Monotherapy (Treatment Group A) | Phase 2 | Advanced Solid Tumor |
| IMM-6-415 | Phase 2 | Advanced Solid Tumor (Phase 1) |
Price & technical context
3-month
-21.0%
6-month
-25.5%
12-month
-36.2%
52-wk range
$3.92–$8.33
vs 50-day MA
-12.3%
vs 200-day MA
-19.2%
Realized vol
89.0%
Max drawdown
-65.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.